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Abstract
Background: Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic
obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD
exacerbations. We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term
exacerbation risk in COPD patients.
Methods: We performed a retrospective analysis of data from a study (ClinicalTrials.gov registration: NCT00419744)
comparing budesonide/formoterol 320/9 μg with formoterol 9 μg (both twice daily) in patients with moderate-to-very-
severe COPD; reliever salbutamol 90 μg was provided. First occurrence of reliever use >4 (low), >10 (medium), and >20
(high) inhalations/day was assessed as a predictor of short-term (3-week) exacerbation risk. Mean daily reliever use in
the week preceding the 2-month visit was investigated as a predictor of the long-term (10-month) exacerbation risk,
using intervals of 2–5, 6–9, and ≥10 inhalations/day.
Results: Overall, 810 patients were included (61 % male; mean age 63.2 years; post-bronchodilator forced expiratory
volume in 1 s 37.7 % of predicted). First occurrence of low, medium, or high reliever use was predictive of an
exacerbation within the following 3 weeks; exacerbation risk increased significantly with increasing reliever use. Mean
reliever use over 1 week was predictive of long-term exacerbation risk. Patients with mean use of 2–5, 6–9, and ≥10
inhalations/day exhibited 21 %, 67 %, and 135 % higher exacerbation rates, respectively, in the following 10 months,
compared with <2 inhalations/day. Budesonide/formoterol was associated with lower short- and long-term
exacerbation risk than formoterol in all reliever-use groups.
Conclusions: SABA reliever use is a predictor of short- and long-term exacerbation risk in moderate-to-very-severe
COPD patients with a history of exacerbations receiving budesonide/formoterol or formoterol.
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Background
The global burden of symptoms in patients with chronic
obstructive pulmonary disease (COPD) is high [1]. Under-
recognition and under-treatment of COPD can have a
significant impact on day-to-day activities and quality of
life for patients, resulting in avoidable disease burden,
activity impairment [1], and hospitalization risk [2].
It remains unclear which endpoints most sensitively
reflect the day-to-day variation in symptoms in patients
with COPD. Ideally, outcomes in COPD trials should
reflect the real-world behavior of patients as well as the
potential of treatment to influence both current disease
state and future risk [3]. The forced expiratory volume
in 1 s (FEV1) is a reproducible and responsive measure-
ment that reflects aspects of the pathophysiology char-
acterizing COPD. However, FEV1 impairment is only
weakly related to overall patient well-being [4, 5], and
other endpoints are needed that are easier to obtain in
routine clinical practice and that reflect the day-to-day
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impact of COPD on the patient, in order to guide treat-
ment decisions [6, 7]. New symptom-based question-
naires address this need, but they may neglect the
important information patients report during routine of-
fice visits or in surveys accompanied by objective mea-
sures of symptom impact [8]. An example of this type of
information is the frequency with which patients use re-
liever medication to control symptoms experienced in
the real world.
In asthma trials, the use of short-acting β2-agonists
(SABA) as reliever medication to decrease symptoms
has been accepted as a measure of day-to-day asthma
control [9]. This outcome is included in widely used
asthma control questionnaires as a surrogate measure
of symptom frequency and a reflection of treatment
efficacy [10, 11]. Until relatively recently, SABAs were
prescribed to COPD patients as background mainten-
ance therapy 1–4 times per day and, traditionally,
their frequency of use has not been considered to reflect
the variability of symptoms and patients’ responses. With
the widespread use of long-acting inhaled bronchodila-
tors as first-line maintenance medication in COPD [12],
SABAs are now seen as reliever medication in COPD
[13]. Thus, by analogy with asthma, reliever use in COPD
may be a sensitive marker of symptom variability [14]
and of the extent to which an intervention improves
symptom control. Conversely, since increased reliever
use is an indicator of sub-optimal control in asthma, it
could have a similar significance in COPD, reflecting
worsening symptom control or an impending exacerba-
tion. Evidence already exists to show that, compared with
as-needed SABA use, regular SABA use is not associated
with additional benefit across a range of clinical and
functional outcomes in COPD [15].
We hypothesized that more SABA taken as reliever
medication would predict increased short- and long-term
risk of exacerbations in patients with COPD, and tested
our hypothesis retrospectively by analyzing reliever use
collected by electronic diary recording in patients who
participated in a clinical trial of budesonide/formoterol
(BUD/FORM) or formoterol (FORM) [16].
Methods
This retrospective analysis was undertaken on data
collected in a study (ClinicalTrials.gov registration:
NCT00419744) comparing fixed-dose combination BUD/
FORM with FORM monotherapy, in which electronic
diaries were used to record as-needed SABA reliever use
administered using a pressurized metered-dose inhaler
(pMDI) [16]. The study evaluated the effect of mainten-
ance treatment with BUD/FORM or FORM on COPD
exacerbations, defined as COPD worsening leading to oral
corticosteroid therapy and/or hospitalization, in patients
with moderate-to-very-severe COPD [12] who had a
history of one or more exacerbations in the previous year.
The study protocol was approved by an institutional re-
view board for each of the clinical sites and written in-
formed consent was obtained from patients or guardians
before any study procedures were initiated. The study was
conducted in accordance with the Declaration of Helsinki,
Good Clinical Practice and applicable local regulations.
Study design and methods
The full methodology of this trial has been published
previously [16]. Following a 2-week run-in period,
current COPD medications were discontinued and eli-
gible patients who met inclusion criteria were random-
ized to twice-daily BUD/FORM pMDI 160/4.5 μg × 2
inhalations (320/9 μg), BUD/FORM pMDI 80/4.5 μg × 2
inhalations (160/9 μg), or formoterol dry powder inhaler
(DPI) 4.5 μg × 2 inhalations (9 μg). Patients were provided
with the SABA salbutamol (albuterol) 90 μg × 2 inhala-
tions via a pMDI to administer as reliever medication
throughout the study. Medications were not escalated
during the trial; however, medications allowed during a
COPD exacerbation were oral corticosteroids, single in-
jection parenteral corticosteroids (not depot formula-
tions), xanthines, and inhaled or nebulized ipratropium
or β2-agonists. Symptoms, and morning and evening peak
expiratory flow, were measured daily prior to the adminis-
tration of the morning and evening dose of study medica-
tion. Use of reliever medication was recorded in the
morning and evening as number of inhalations.
Patients receiving twice-daily BUD/FORM pMDI 160/
4.5 μg × 2 inhalations (320/9 μg) and formoterol dry
powder inhaler (DPI) 4.5 μg × 2 inhalations (9 μg) were
included in the present analysis. Patients receiving the
lower dose of BUD/FORM were excluded from the
present analysis as it is not a registered product.
Statistical analysis
We assessed two risk profiles for SABA use and
exacerbations.
Short-term exacerbation risk (21 days)
The short-term exacerbation risk was evaluated as the
relationship between a patient reaching a certain
threshold of reliever use in a single day and the prob-
ability of having an exacerbation in the next 21 days.
This short-term risk was described by analysis of time
to first exacerbation after the first time a patient used
more than the specified number of SABA inhalations.
This was presented descriptively using Kaplan-Meier
graphs for reliever use thresholds of >4 (low use), >10
(medium use), and >20 (high use) inhalations in a single
day for both treatment groups, with ≥0 inhalations (i.e. all
patients) as a reference group. Both the reliever use
thresholds and 21-day time period were defined empirically;
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the reliever use thresholds broadly reflected use in
clinical practice based on the authors’ clinical expert-
ise, and the time period considered both the longest
period of time following deviation from daily reliever
use and the known evolution of COPD exacerbations
[17]. The data were analyzed using a log-rank test; p-
values were calculated for the comparisons of all
groups and then individually against the reference
group.
Long-term exacerbation risk (months 3–12)
The long-term exacerbation risk was evaluated as the re-
lationship between mean reliever use during stable treat-
ment in the week before the 2-month study visit and
probability of an exacerbation occurring in months 3–12
of the study. This risk was described by analysis of the
number of exacerbations for mean reliever use intervals
(2–5, 6–9, and ≥10 inhalations/day: low, medium, and
high reliever use, respectively), compared with mean
reliever use <2 inhalations per day (infrequent). The
long-term mean reliever use intervals were defined em-
pirically to broadly reflect mean reliever use over a week
in clinical practice based on the authors’ clinical expert-
ise, and a 10-month time period was chosen to allow the
longest time period between the 2-month visit and study
end. We also determined long-term 10-month risk by
analyzing the exacerbation rates by treatment in pa-
tients: i) reaching mean reliever use thresholds of ≥2, ≥6,
and ≥10 inhalations per day; and ii) with mean number of
inhalations (< or ≥) in a range from zero to 12 inhala-
tions/day.
The analyses were performed using a Poisson regres-
sion analysis, adjusted for over-dispersion, with treat-
ment as factor included for the first analysis. The
analyses were not adjusted for additional covariates.
Both analyses were presented with rates and ratios with
95 % confidence intervals (CI) and p-values.
The distribution of the frequency of patients’ reliever
use on each of the study treatments was analyzed using
Fisher’s exact test.
Results
In total, 810 patients with moderate-to-very-severe
COPD were included: 61 % male; mean age (range)
Table 1 Baseline characteristics of patients included in this post-hoc analysis of the Sharafkhaneh et al. study [16]
BUD/FORM FORM Total
(n = 407) (n = 403) (n = 810)
Male, n (%) 262 (64.4) 229 (56.8) 491 (60.6)
Age, years (range) 63.8 (40–86) 62.5 (40–87) 63.2 (40–87)
Pre-BD FEV1, % predicted 33.0 (10.5) 32.4 (10.1) 32.7 (10.3)
Post-BD FEV1, % predicted 37.9 (11.8) 37.5 (12.4) 37.7 (12.1)
Pre-BD FEV1/FVC ratio, % 45.9 (11.3) 46.1 (11.1) 46.0 (11.2)
Smoking history
Current smokers, n (%) 138 (33.9) 154 (38.2) 292 (36.0)
Pack-years (range) 52.6 (10–200) 52.2 (10–258) 52.4 (10–258)
Most common COPD medications before run-in, n (%)
β2-adrenergic agonists (SABA/LABA) 320 (78.6) 321 (79.7) 641 (79.1)
Adrenergics/other drugs for obstructive airway diseases 198 (48.6) 196 (48.6) 394 (48.6)
Long-acting muscarinic antagonist 123 (30.2) 109 (27.0) 232 (28.6)
Inhaled corticosteroids 108 (26.5) 117 (29.0) 225 (27.8)
No. of exacerbations in the past 12 months, n (%)
1 244 (60.0) 234 (58.1) 478 (59.0)
2 95 (23.3) 99 (24.6) 194 (24.0)
3 36 (8.8) 38 (9.4) 74 (9.1)
4 22 (5.4) 19 (4.7) 41 (5.1)
≥ 5 10 (2.5) 13 (3.2) 23 (2.8)
Mean reliever use, inhalations/daya 5.8 (4.6) 6.0 (4.5) 5.9 (4.6)
Patients taking ICS at baseline, n % 108 (26.5) 117 (29.0) 225 (2.8)
Data shown as mean (±SD), unless otherwise stated. Current smokers include habitual and occasional smokers
BD bronchodilator, BUD budesonide, FEV1 forced expiratory volume in 1 s, FORM formoterol, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting
β2-agonists, SABA short-acting β2-agonists, SD standard deviation
aBaseline: 2-week run-in period
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63.2 (40–87) years; mean (±SD) post-bronchodilator
FEV1 37.7 (12.1) % of predicted; 27.8 % of patients
received inhaled corticosteroids before study run-in
(BUD/FORM: 26.5 %, FORM: 29.0 %). Demographic
and baseline clinical characteristics of patients included in
this post-hoc analysis generally were similar across treat-
ment groups (Table 1) [16]. Data were available for 807
patients in the short-term exacerbation risk analysis: 692,
351, and 91 patients reached the low (>4 inhalations/day),
medium (>10 inhalations/day), and high (>20 inhalations/
day) reliever use thresholds, respectively (patient n values
are cumulative, i.e. all patients in the >20 subgroup are
also in the >4 and >10 subgroups). In addition, data were
available for 674 patients in the long-term exacerbation
risk analysis: 234, 155, and 92 patients reached the mean
number of inhalations/day for inclusion in the low (2–5
Fig. 1 Short-term (days 0–21) exacerbation risk. Kaplan-Meier plot of patients with occurrence of an exacerbation after they used for the
first time >4, >10, or >20 inhalations of salbutamol per day in a) FORM and b) BUD/FORM treatment groups. Data for 16 patients are
missing from baseline to day 0. BUD budesonide, COPD chronic obstructive pulmonary disease, FORM formoterol
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inhalations/day), medium (6–9 inhalations/day), and high
(>10 inhalations/day) reliever use subgroups, respectively.
Short-term exacerbation risk (21 days)
The first occurrence of reliever use beyond a certain
threshold, i.e. low, medium, or high reliever use in a single
day, was predictive of an exacerbation within the following
3 weeks (Fig. 1). The time to first exacerbation differed be-
tween the reliever use groups for both BUD/FORM and
FORM (p < 0.001; Fig. 1). In addition, there was a signifi-
cant increase in the risk of an exacerbation for patients
who had medium and high reliever use compared with
the reference group (≥0 inhalations/day) for both the
BUD/FORM (p = 0.002 and <0.0001, respectively) and
FORM (p = 0.02 and <0.0001, respectively) groups.
Long-term exacerbation risk (months 3–12)
Mean daily reliever use over 1 week preceding the 2-
month visit was identified as a predictor of the long-
term 10-month (i.e. months 3–12) probability of an
exacerbation. Patients with a mean use of 2–5, 6–9,
and ≥10 inhalations exhibited 21 %, 67 %, and 135 %,
respectively, greater exacerbation rates in the following
10 months relative to patients with a mean use of <2 in-
halations/day; the difference being significant for the 6–9
and ≥10 groups (Table 2). For both treatments, long-term
10-month exacerbation rates were greater whenever mean
reliever use exceeded thresholds, in the range from 0–12
inhalations/day in the week preceding the 2-month visit
(Fig. 2). In addition, there were more infrequent re-
liever users in the BUD/FORM group than FORM
group and, consequently, fewer patients with ≥2, ≥6,
or ≥10 inhalations of reliever medication per day; this
was most apparent at higher reliever use (Table 3). Pa-
tients randomized to BUD/FORM had a lower risk of
exacerbations than the FORM group (Fig. 3). Patients
with higher mean daily reliever use in the week pre-
ceding the 2-month visit had a higher rate of exacer-
bations during months 3–12 than those with lower
mean daily reliever use, over a range of cut-points
(Table 2 and Fig. 3). This was true for both BUD/
FORM and FORM recipients.
Discussion
In this analysis, the daily number of inhalations of SABA
needed for relief of symptoms was a predictor for future
exacerbations in patients with COPD and a history of
exacerbations in a study of combination BUD/FORM as
maintenance therapy. SABA use predicted both short-
and long-term risk of exacerbations. High SABA use in a
single day was a predictor of the short-term probability
Fig. 2 Long-term (months 3–12) exacerbation rate by reliever use
thresholds. Long-term (months 3–12) exacerbation rates for patients
receiving a) FORM and b) BUD/FORM with a mean number of
inhalations less than, and greater than or equal to, reliever use in the
range from zero to 12 inhalations/day in the week preceding the
2-month visit. BUD budesonide, FORM formoterol
Table 2 Long-term exacerbation rate. Long-term (months 3–12)
exacerbation rate in all patients, based on cut-points of ≥2, ≥6,






95 % CI P-value
<2 0.596 (0.470, 0.756)
2–5 0.724 (0.594, 0.882)
6–9 0.996 (0.806, 1.230)
≥10 1.403 (1.115, 1.766)
2–5 versus <2 1.214 (0.891, 1.654) 0.22
6–9 versus <2 1.670 (1.215, 2.296) 0.0016
≥10 versus <2 2.353 (1.687, 3.282) <0.001
CI confidence interval
aRates are normalized for 10 months and expressed as events per year.
Analysis adjusted for treatment effects
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of exacerbation in the following 21 days, whereas the
average daily SABA use over 1 week of stable mainten-
ance treatment was a strong predictor of an exacerba-
tion in the following 10 months. This was true for
patients taking BUD/FORM and FORM alone; however,
patients treated with BUD/FORM had a lower short-
and long-term risk of exacerbation compared with
FORM monotherapy.
Although a relationship between as-needed SABA
use and exacerbations in patients with COPD has
long been suspected by clinicians, to our knowledge
this is the first systematic investigation demonstrating
this relationship. Indeed, although an increasing num-
ber of studies testing the efficacy of long-acting broncho-
dilators have used this index as an objective measure of
the impact of treatment and a surrogate marker for
breakthrough symptoms [18–21], none have specifically
analyzed the data in relation to the predictive capacity of
as-needed SABA use in this context. In this analysis of
data from a randomized, controlled study, we showed
that as-needed SABA use in COPD patients can predict
exacerbation risk over the short (≤21 days) and long
(≤10 months) term, if patients are taking appropriate
doses of long-acting β2-agonist either alone or in com-
bination with an inhaled corticosteroid. Our data suggest
that for COPD, as in asthma [22], reliever use may be im-
plemented as an important parameter for disease stability
and future exacerbation risk. If our results are confirmed
in other studies, it may be useful for clinicians to monitor
patterns of reliever medication use so that they can iden-
tify patients at risk for an exacerbation, take steps to pre-
vent the occurrence of a COPD exacerbation and ensure
that when these events do occur, they are more rapidly
identified and effectively treated. Similarly, patients may
be educated to recognize increasing reliever use as a
warning sign for an exacerbation and to take steps early
to prevent further deterioration.
While we consider these findings to be robust for
this group of patients with moderate-to-very-severe
COPD and a history of exacerbations, further studies
in patients with milder disease are needed before the
predictive capacity of the use of SABA as a reliever
can be generalized to all symptomatic patients with
COPD. Ideally, for implementation in clinical trials, the
findings should be confirmed in other large datasets in
Fig. 3 Long-term (months 3–12) exacerbation rate by treatment group. Long-term (months 3–12) exacerbation rate by treatment group, for patients
reporting <2, ≥2, ≥6, or ≥10 inhalations/day in the week preceding the 2-month visit. P-values are for the analysis of BUD/FORM versus FORM. BUD
budesonide, FORM formoterol
Table 3 Number of patients reporting <2, ≥2, ≥6, or ≥10




BUD/FORM (n = 349) FORM (n = 325) P valuea
Patients with cut-point inhalations/day, n (%)
<2 114 (32.7) 79 (24.3) 0.017
≥2 235 (67.3) 246 (75.7) 0.017
≥6 111 (31.8) 136 (41.8) 0.007
≥10 27 (7.7) 65 (20.0) <0.001
Patient n values are cumulative (i.e. all patients in the ≥10 group are also in
the ≥2 and ≥6 groups) and represent the number of patients remaining in the
analysis for the week before the 2-month visit
BUD budesonide, FORM formoterol
aP-values are for the analysis of BUD/FORM versus FORM
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which similar instructions have been given to participants,
with records of SABA use kept in a comparable way
throughout the study. In addition, further studies would
enable assessment of the degree of individual variability
and clarify the ideal reliever use cut-points in predicting
COPD exacerbations. We wished to validate our findings
in a larger study population receiving similar BUD/FORM
and FORM doses and recording reliever use, using data
from five randomized controlled trials of BUD/FORM
[17, 23–26], including the use of BUD/FORM in com-
bination with a long-acting muscarinic antagonist [17].
However, methodological differences between the stud-
ies, specifically a mix of methodology (paper versus elec-
tronic diaries, different study duration and devices),
meant that this analysis could not be undertaken in a
suitably rigorous manner.
The reliever use categories in the present analysis
were defined empirically to broadly reflect use in clin-
ical practice based on the authors’ clinical expertise,
and future analyses should validate reliever use cat-
egories to identify specific thresholds that may predict
future exacerbations. However, even in the absence of
further validation, measures of SABA reliever use could
be incorporated into risk prediction tools for exacerba-
tions to initiate early treatment and potentially mitigate an
upcoming exacerbation. We have previously developed a
risk prediction tool (SCOPEX) based on a range of demo-
graphic and baseline parameters from a pooled database
of BUD/FORM COPD studies; data from this tool showed
that higher mean daily reliever use was a dominant pre-
dictor of a COPD exacerbation in the next 6 months [27].
In agreement with the current analysis, the risk prediction
tool showed that FORM was associated with a higher ex-
acerbation risk than BUD/FORM.
As with the original study [16], it is unclear whether
discontinuation of inhaled corticosteroids in those pa-
tients who received FORM alone contributed to worse
exacerbation outcomes compared with those receiving
BUD/FORM. Long-acting β2-agonist monotherapy is
not recommended in patients with severe-to-very-severe
COPD, limiting the interpretability of our data in the
FORM only group. We note, however, a trend to under-
take studies assessing bronchodilators alone even in se-
vere/Group D patients, so the issue of a non-inhaled
corticosteroid approach to Group D – especially those
who do not exacerbate frequently – is still being dis-
cussed. In addition, we cannot verify whether the number
of daily inhalations or occasions of SABA use as reliever
medication was exactly as patients recorded in their elec-
tronic diaries. However, reliever use was recorded twice
daily and entries were permitted only in specific time
windows (morning and evening), which prevented retro-
spective recordings. It is well known that paper diaries
may permit retrospective and fictitious entries, and even
electronic diaries may suffer from recall errors [28, 29].
Optimally, electronic inhaler adherence monitoring should
be used to confirm these records, but the data we ana-
lyzed were taken from a study in which this was not
undertaken.
Conclusions
SABA reliever use was a predictor of short- (≤21 days)
and long-term (≤10 months) risk of exacerbations in pa-
tients with moderate-to-very-severe COPD and a history
of exacerbations receiving combination BUD/FORM or
FORM monotherapy. Mean reliever use over 1 week
predicted exacerbation risk, and this risk increased fur-
ther with a higher number of inhalations of reliever/day.
These data suggest that SABA use is an important and
practical outcome for assessing both current control and
future risk in patients with COPD. Additional clinical
trials and effectiveness studies of COPD patients with
different disease severity and exacerbation history are
needed to validate SABA use as a predictor of exacerba-
tions in both clinical trials and in clinical practice.
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